SGE vs. FBT, WISE, SXS, SCT, DARK, RSW, CCC, KNOS, TRST, and ATG
Should you be buying The Sage Group stock or one of its competitors? The main competitors of The Sage Group include First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (FBT), Wise (WISE), Spectris (SXS), Softcat (SCT), Darktrace (DARK), Renishaw (RSW), Computacenter (CCC), Kainos Group (KNOS), Trustpilot Group (TRST), and Auction Technology Group (ATG). These companies are all part of the "computer and technology" sector.
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) and The Sage Group (LON:SGE) are both computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, community ranking, media sentiment and valuation.
In the previous week, The Sage Group had 4 more articles in the media than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. MarketBeat recorded 5 mentions for The Sage Group and 1 mentions for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. The Sage Group's average media sentiment score of 0.80 beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's score of 0.66 indicating that First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is being referred to more favorably in the media.
68.0% of The Sage Group shares are owned by institutional investors. 0.7% of The Sage Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
The Sage Group has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than The Sage Group, indicating that it is currently the more affordable of the two stocks.
The Sage Group has a consensus target price of GBX 1,052.50, indicating a potential downside of 10.27%. Given First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's higher possible upside, analysts clearly believe The Sage Group is more favorable than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation.
The Sage Group received 448 more outperform votes than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation when rated by MarketBeat users. However, 66.67% of users gave First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation an outperform vote while only 44.94% of users gave The Sage Group an outperform vote.
The Sage Group has a net margin of 9.66% compared to The Sage Group's net margin of 0.00%. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity of 15.05% beat The Sage Group's return on equity.
Summary
The Sage Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 12 of the 15 factors compared between the two stocks.
Get The Sage Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
The Sage Group Competitors List
Related Companies and Tools
